Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : VBIV save search
VBI Vaccines Reports Full Year 2023 Financial Results
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: -3.45%
H: 14.29%
C: 10.71%
year financial results
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
Published: 2024-04-03 (Crawled : 14:30) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 0.86%
H: 7.92%
C: 6.56%
vbi-1901 tumor response glioblastoma study
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
| Email alert
Add to watchlist
partnership vaccine platform
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results
Published: 2024-03-22 (Crawled : 11:00) - prnewswire.com
ANTX | $2.43 2.1% 2.06% 100K
|
|
| O: -1.21%
H: 6.73%
C: 1.83%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.89%
C: -0.4%
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 0.18%
H: 4.24%
C: 1.63%
update financial results
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
Published: 2024-02-14 (Crawled : 13:30) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 9.17%
H: 0.72%
C: -20.06%
license agreement
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Published: 2024-02-14 (Crawled : 00:00) - prnewswire.com
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 9.17%
H: 0.72%
C: -20.06%
brii-179 transfer acquire commercial technology agreement
VBI Vaccines Reports Third Quarter 2023 Financial Results
Published: 2023-11-14 (Crawled : 00:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: -2.12%
H: 3.78%
C: 0.78%
AGEN | $5.3 6.64% 6.23% 1.5M
|
Health Technology
|
| O: 5.0%
H: 10.95%
C: 10.84%
financial results
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 23:00) - prnewswire.com
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 3.92%
H: 4.3%
C: 3.35%
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: -2.12%
H: 3.78%
C: 0.78%
meeting cure liver
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
Published: 2023-10-26 (Crawled : 14:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 0.81%
H: 28.0%
C: 20.8%
vaccine program technology
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 8.63%
H: 8.82%
C: -1.68%
vbi-2901 vaccine
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
Published: 2023-09-07 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 6.56%
H: 0.62%
C: -6.92%
vbi-1901 study
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
Published: 2023-09-06 (Crawled : 12:00) - vbivaccines.com
CYDY | $0.1509 0.06% 810K
|
Manufacturing
|
| O: 0.49%
H: 1.94%
C: 1.94%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 0.81%
H: 0.8%
C: -2.4%
TRIB | $1.81 -3.72% -3.87% 5.7K
|
Health Technology
|
| O: -0.38%
H: 1.87%
C: 1.86%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.83%
H: 0.19%
C: -0.09%
RGEN | $157.12 0.04% 0.04% 380K
|
Health Technology
|
| O: -0.47%
H: 0.45%
C: -0.51%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -1.56%
H: 0.0%
C: 0.0%
AVID | $27.04 0.07% 630K
|
Technology Services
|
| O: 0.26%
H: 0.37%
C: 0.26%
brii-179 hepatitis treatment topline results study
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B
Published: 2023-09-06 (Crawled : 11:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 0.81%
H: 0.8%
C: -2.4%
brii-179 hepatitis treatment topline results study
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
Published: 2023-08-22 (Crawled : 17:00) - biospace.com/
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: 0.71%
H: 2.11%
C: 0.86%
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: -1.61%
H: 1.64%
C: 1.64%
results
VBI Vaccines Reports Second Quarter 2023 Financial Results
Published: 2023-08-14 (Crawled : 13:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: -2.38%
H: 9.76%
C: 9.76%
financial results
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
Published: 2023-07-24 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: -1.4%
H: 2.84%
C: -3.55%
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
Published: 2023-07-19 (Crawled : 13:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: 3.6%
H: 6.44%
C: 4.17%
prehevbri hepatitis netherlands
VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
Published: 2023-07-06 (Crawled : 14:20) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: -41.32%
H: 0.0%
C: -16.9%
direct offering
Brii Biosciences Provides Latest Clinical Development and Corporate Updates
Published: 2023-07-06 (Crawled : 07:00) - biospace.com/
ANTX | $2.43 2.1% 2.06% 100K
|
|
| O: 0.34%
H: 2.05%
C: 0.11%
VIR | $7.96 0.0% 1.1M
|
Health Technology
|
| O: -1.35%
H: 0.25%
C: -5.07%
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: -41.32%
H: 0.0%
C: -16.9%
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure
Published: 2023-07-06 (Crawled : 07:00) - biospace.com/
VBIV | $0.6396 1.57% 1.55% 160K
|
Health Technology
|
| O: -41.32%
H: 0.0%
C: -16.9%
hepatitis
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.